Toward indole postbiotics precision therapy via AI-powered drug delivery technologies

IF 5.6 2区医学 Q1 IMMUNOLOGY

Current Opinion in Immunology Pub Date : 2026-02-01 Epub Date: 2025-11-11 DOI:10.1016/j.coi.2025.102692

Puccetti Matteo , Pariano Marilena , Wojtylo Paulina Anna , Ricci Maurizio , Stefano Giovagnoli

{"title":"Toward indole postbiotics precision therapy via AI-powered drug delivery technologies","authors":"Puccetti Matteo , Pariano Marilena , Wojtylo Paulina Anna , Ricci Maurizio , Stefano Giovagnoli","doi":"10.1016/j.coi.2025.102692","DOIUrl":null,"url":null,"abstract":"<div><div>Recent advancements in microbiome research have revealed the restorative capacities of postbiotics, including indole and its derivatives generated via bacterial tryptophan metabolism. Widespread in prokaryotic and eukaryotic communities, indole and its derivatives are uniquely suited to promote host physiology and homeostasis at the host/microbe interface. In addition to suppressing the bacterial pathogenesis, the antioxidant, anti-inflammatory, antidiabetic, antihypertensive, immunomodulatory, and metabolic activities of indole and its derivatives make these postbiotics an attractive therapeutic option. However, their clinical translation is impeded by pharmacokinetic constraints, structural promiscuity, and formulation difficulties. This review examines the current status of indole bioactivities, identifies translational challenges, and suggests the use of artificial intelligence as a method for establishing a comprehensive framework for future translational development.</div></div>","PeriodicalId":11361,"journal":{"name":"Current Opinion in Immunology","volume":"98 ","pages":"Article 102692"},"PeriodicalIF":5.6000,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current Opinion in Immunology","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0952791525001682","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/11/11 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"IMMUNOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Recent advancements in microbiome research have revealed the restorative capacities of postbiotics, including indole and its derivatives generated via bacterial tryptophan metabolism. Widespread in prokaryotic and eukaryotic communities, indole and its derivatives are uniquely suited to promote host physiology and homeostasis at the host/microbe interface. In addition to suppressing the bacterial pathogenesis, the antioxidant, anti-inflammatory, antidiabetic, antihypertensive, immunomodulatory, and metabolic activities of indole and its derivatives make these postbiotics an attractive therapeutic option. However, their clinical translation is impeded by pharmacokinetic constraints, structural promiscuity, and formulation difficulties. This review examines the current status of indole bioactivities, identifies translational challenges, and suggests the use of artificial intelligence as a method for establishing a comprehensive framework for future translational development.

查看原文本刊更多论文

通过人工智能给药技术实现吲哚后生物精准治疗。

微生物组研究的最新进展揭示了后生物的恢复能力，包括吲哚及其衍生物通过细菌色氨酸代谢产生。吲哚及其衍生物广泛存在于原核和真核生物群落中，特别适合于促进宿主生理和宿主/微生物界面的稳态。除了抑制细菌发病机制外，吲哚及其衍生物的抗氧化、抗炎、降糖、降压、免疫调节和代谢活性使这些后生物制剂成为一种有吸引力的治疗选择。然而，它们的临床转化受到药代动力学限制、结构混杂和配方困难的阻碍。本文综述了吲哚生物活性的现状，确定了转化面临的挑战，并建议使用人工智能作为建立未来转化发展的综合框架的方法。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Current Opinion in Immunology 医学-免疫学

CiteScore

13.30

自引率

1.40%

发文量

审稿时长

67 days

期刊介绍： Current Opinion in Immunology aims to stimulate scientifically grounded, interdisciplinary, multi-scale debate and exchange of ideas. It contains polished, concise and timely reviews and opinions, with particular emphasis on those articles published in the past two years. In addition to describing recent trends, the authors are encouraged to give their subjective opinion of the topics discussed. In Current Opinion in Immunology we help the reader by providing in a systematic manner: 1. The views of experts on current advances in their field in a clear and readable form. 2. Evaluations of the most interesting papers, annotated by experts, from the great wealth of original publications. Current Opinion in Immunology will serve as an invaluable source of information for researchers, lecturers, teachers, professionals, policy makers and students. Current Opinion in Immunology builds on Elsevier''s reputation for excellence in scientific publishing and long-standing commitment to communicating reproducible biomedical research targeted at improving human health. It is a companion to the new Gold Open Access journal Current Research in Immunology and is part of the Current Opinion and Research(CO+RE) suite of journals. All CO+RE journals leverage the Current Opinion legacy-of editorial excellence, high-impact, and global reach-to ensure they are a widely read resource that is integral to scientists'' workflow.